{"title": "New Study Confirms Typhoid Vaccine Safety, Immune Response in Children", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2016-01-11", "cleaned_text": "August 09, 2022 | [January Payne](mailto:january.payne@som.umaryland.edu) Contact January Payne Director of Public Relations University of Maryland School of Medicine Office of Public Affairs & Communications c: 443-203-8183 e: january.payne@som.umaryland.edu t: @januarypayne Related stories Thursday, 2023 [Small Study Shows Promise for Antimalarial Monoclonal Antibody to Prevent Malaria](https://www.medschool.umaryland.edu/news/2023/Small-Study-Shows-Promise-for-Antimalarial-Monoclonal-Antibody-to-Prevent-Malaria.html) A monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in by researchers at the University of Maryland School of Medicine (UMSOM). Monday, August 08, 2022 [New Study Finds Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against Omicron Subvariant BA.5](https://www.medschool.umaryland.edu/news/2022/New-Study-Finds-Rapid-Decline-in-Vaccine-Boosted-Neutralizing-Antibodies-Against-Omicron-Subvariant-BA5.html) A study led in part by investigators at the University of Maryland School of Medicine's (UMSOM) Center for Vaccine Development and Global Health found that although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, those antibody levels decrease substantially within three months. Kirsten E. Lyke, MD, Professor of Medicine at UMSOM and scientist at CVD, is Co-Chair and site Principal Investigator for the study, and Meagan Deming, MD, PhD, Assistant Professor of Medicine at the UMSOM, also a scientist at CVD, is Vice-Chair of the study, which is a collaboration between investigators at the UMSOM's CVD and the Institute of Human Virology (IHV). Thursday, March 24, 2022 [UM School of Medicine Leads Research to Assess Meningococcal Vaccine for Infants and Young Children in Africa](https://www.medschool.umaryland.edu/news/2022/UM-School-of-Medicine-Leads-Research-to-Assess-Meningococcal-Vaccine-for-Infants-and-Young-Children-in-Africa.html) Researchers at the University of Maryland School of Medicine (UMSOM)'s Center for Vaccine Development & Global Health (CVD) are leading a study to evaluate the use of a pentavalent - or five in one - meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa. This is the final and pivotal study for World Health Organization (WHO) prequalification of this vaccine, which is the last stage to make the vaccine available for low- and middle-income countries. Thursday, September 16, 2021 [First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever](https://www.medschool.umaryland.edu/news/2021/First-Efficacy-Results-from-Africa-find-Typhoid-Vaccine-to-offer-84-Percent-Protection-against-Typhoid-Fever.html) A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) - the only typhoid vaccine licensed for children as young as 6 months - is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV. Tuesday, March 20, 2018 [UMSOM Vaccine Experts Lead Trial on Avian Flu Vaccine](https://www.medschool.umaryland.edu/news/2018/UMSOM-Vaccine-Experts-Lead-Trial-on-Avian-Flu-Vaccine.html) Vaccine experts at the University of Maryland School of Medicine (UMSOM) have begun multiple clinical trials of vaccines designed to protect against H7N9, an avian influenza virus that was first reported in humans in 2013 in China. Wednesday, August 02, 2017 [UM School of Medicine Receives $2 Million Grant for HIV Research in Malawi](https://www.medschool.umaryland.edu/news/2017/UM-School-of-Medicine-Receives-2-Million-Grant-for-HIV-Research-in-Malawi.html) The University of Maryland School of Medicine's (UM SOM) Institute for Global Health (IGH) and the Institute of Human Virology (IHV) have been awarded a $2 million five-year grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to study the impact exposure to HIV has on the immune systems of infants in utero and how those changes impact the ability of infants to fight off infections after birth. Friday, December 23, 2016 [Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease](https://www.medschool.umaryland.edu/news/2016/Trial-Results-Confirm-Ebola-Vaccine-Provides-High-Protection-Against-Disease.html) An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine (UM SOM). Monday, January 11, 2016 [UM SOM to Collaborate with Industry to Develop a Vaccine to Prevent Common, Deadly Infection](https://www.medschool.umaryland.edu/news/2016/UM-SOM-to-Collaborate-with-Industry-to-Develop-a-Vaccine-to-Prevent-Common-Deadly-Infection.html) The Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM) will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients "}